News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Roche says the move marks a step forward in its digital transformation strategy
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The receipt of this order further strengthens the company's position in the global pharmaceutical market
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Subscribe To Our Newsletter & Stay Updated
